English, Article edition: Cost-Utility Analysis of Survival with Epoetin-Alfa versus Placebo in Stage IV Breast Cancer Silas C. Martin; Dennis D. Gagnon; Lucy Zhang; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118939
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Utility Analysis of Survival with Epoetin-Alfa versus Placebo in Stage IV Breast Cancer
Author
  • Silas C. Martin
  • Dennis D. Gagnon
  • Lucy Zhang
  • Carsten Bokemeyer
  • Marinus Van Marwijk Kooy
  • Ben van Hout
Physical Description
  • article
Notes
  • Background: In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL. Although the study was not designed or powered to evaluate survival, a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p =​ 0.126]). Objectives: To determine the incremental cost utility of epoetin-alfa versus placebo in anaemic patients with stage IV breast cancer from a UK National Health Service perspective. Methods: Patient data regarding transfusions, epoetin-alfa usage, chemotherapy treatment cycles, and adverse events were recorded, with survival follow-up for 12-36 months post-study. Stage IV breast cancer therapy costs were collected by surveying UK oncologists, and utilities for associated health states were from published sources. Costs were in British pounds and year 2000 values. Costs and benefits were jointly determined for the stage IV breast cancer subgroup (n =​ 55). Incremental cost-utility ratios (ICURs) were calculated assuming a 6% annual discount rate for costs and a 1.5% annual discount rate for benefits. Bootstrap simulations (10 Results: The ICUR for epoetin-alfa treatment was Lstg 8851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit =​ 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of Lstg 30 Conclusions: The available data suggest a high probability of favourable cost- utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy. Additional studies are warranted.
  • Anaemia, Antianaemics, Cost-utility, Epoetin-alfa, Pharmacoeconomics
  • RePEc:wkh:phecon:v:21:y:2003:i:16:p:1153-1169
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment